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2ϩ homeostasis has only recently been investigated. The increased understanding of the role of stromal interaction molecule 1 (STIM1) in regulating SOCE combined with recent studies demonstrating the presence of STIM1 in cardiomyocytes provides support that this pathway co-exists in the heart with the more widely recognized Ca 2ϩ handling pathways associated with excitation-contraction coupling. There is now substantial evidence that STIM1-mediated SOCE plays a key role in mediating cardiomyocyte hypertrophy, both in vitro and in vivo, and there is growing support for the contribution of SOCE to Ca 2ϩ overload associated with ischemia/reperfusion injury. Here, we provide an overview of our current understanding of the molecular regulation of SOCE and discuss the evidence supporting the role of STIM1/Orai1-mediated SOCE in regulating cardiomyocyte function.
store-operated Ca 2ϩ entry; stromal interaction molecule 1; orai1; cardiomyocytes STORE-OPERATED CA 2ϩ ENTRY (SOCE), also known as capacitative calcium entry (CCE), is the major mechanism of Ca 2ϩ entry in nearly all nonexcitable cells (97, 99) . In addition, it is increasingly recognized to co-exist with voltage-gated Ca 2ϩ channels in excitable cells, including neurons, skeletal muscle cells, and cardiomyocytes (1, 38, 45, 83, 121) . In response to inositol 1,4,5-triphosphate (IP 3 )- (43) or ryanodine receptor (RyR)-mediated (3) Ca 2ϩ release from ER/SR stores, SOCE facilitates the influx of Ca 2ϩ from the extracellular space, resulting in a sustained increase in cytosolic Ca 2ϩ levels. Thus, although one of the roles of SOCE is to rapidly refill the depleted ER/SR stores, the subsequent sustained increase in cytosolic Ca 2ϩ also regulates numerous gene transcription pathways (33, 50, 151) . Indeed, aberrant SOCE has been observed in a growing number of diseases including severe combined immunodeficiency, acute pancreatitis, and Alzheimer's disease (86) .
The integration of SOCE into well-established models of Ca 2ϩ homeostasis was hampered for many years by the lack of specific molecular mediators; even as recently as 2004 there was considerable controversy as to the specific mechanisms regulating SOCE (90, 113) . However, in 2005, stromal interaction molecule 1 (STIM1) was found to localize to the ER/SR membrane and shown to function as a primary mediator of SOCE (54, 102) . The putative physiological and pathophysiological roles of SOCE and STIM1 that have been identified to date are summarized in Table 1 . A number of studies have recently reported the presence of STIM1 in adult cardiomyocytes (37, 59, 153) , and consistent with earlier evidence supporting a role for SOCE in regulating cardiac hypertrophy (38) , STIM1 levels were shown to be increased in response to cardiac hypertrophy (37, 59) . Nevertheless, despite evidence that SOCE exists in cardiomyocytes, its wider acceptance as a contributor to cardiomyocyte Ca 2ϩ homeostasis remains limited. Although STIM1 is now widely recognized as a key mediator of SOCE, Orai and canonical transient receptor potential protein (TRPC) families have also been shown to play an important role in regulating SOCE. Therefore, the goal of this article is to provide an overview of our current understanding of the molecular regulation of SOCE and to discuss the evidence supporting the role of STIM1/Orai1-mediated SOCE in cardiomyocyte function and pathology.
SOCE. SOCE is the major Ca 2ϩ entry mechanism in nearly all nonexcitable cells (97, 99) and is typically linked to the activation of inositol 1,4,5-triphosphate (IP 3 ), generating G protein-coupled receptors (GPCRs) (76, 126) . IP 3 binds to the IP 3 receptor (IP 3 R) on the ER/SR membrane, triggering Ca 2ϩ release from ER/SR lumen into the cytosol (76 stores, which is essential for maintaining the proper environment within the ER/SR for protein folding/processing, vesicle trafficking, and cholesterol metabolism (27, 50, 110) . However, SOCE also plays an essential role in a wide variety of physiological functions including exocytosis, enzymatic activity, Ca 2ϩ oscillations, muscle contraction, cell mobility, gene transcription, cell proliferation, inflammation, and apoptosis (4, 33, 50, 100, 127, 151) . SOCE was first described by Putney in 1977, after finding that agonist-activated intracellular Ca 2ϩ release in the parotid gland was followed by an influx of Ca 2ϩ through the plasma membrane and further that this Ca 2ϩ influx was required to refill intracellular Ca 2ϩ stores (95, 98) ; however, the causal relationship between these two Ca 2ϩ sources was not defined until the proposal of the CCE model in 1986 (97) . In this model agonist-activated Ca 2ϩ release triggered extracellular Ca 2ϩ entry through the plasma membrane to directly load the depleted stores (97) . In 1990, after several studies showed that the influx of extracellular Ca 2ϩ first entered the cytosol rather than the intracellular Ca 2ϩ stores (66, 118) and that Ca 2ϩ release alone was sufficient to induce the extracellular Ca 2ϩ influx (117), Putney refined his model to show that the Ca 2ϩ store depletion directly activates Ca 2ϩ entry into the cytosol through Ca 2ϩ channels on the plasma membrane (96), a process now defined as SOCE. Despite the growing appreciation of the biological importance of SOCE, the molecular mechanisms underlying how ER/SR Ca 2ϩ depletion triggered an influx of extracellular Ca 2ϩ through the plasma membrane were the subject of intense debate for nearly two decades until the identification of STIM1 in 2005 (54, 102, 150) .
STIM1. The STIM family comprises two proteins: STIM1 and STIM2, of which STIM1, also known as GOK, has been the most widely studied. STIM1 was first identified as a stromal cell surface molecule that promotes the survival and/or proliferation of pre-B lymphocytes (80) ; it was also found to be a recessive tumor suppressor (103, 104) . However, in 2005, STIM1 was shown to predominantly localize in the ER/SR membrane where it acts as an ER/SR Ca 2ϩ sensor and mediates SOCE (54, 102) . The importance of STIM1/2 in organismal physiology is emphasized by the fact that global STIM1 gene deletion in mice is 100% lethal within 2 days after birth, whereas mice lacking STIM2 survive until 4 to 5 wk of age (76) .
STIM1 is a ubiquitously expressed type I membrane protein containing a series of structural domains within its polypeptide sequences (Fig. 1) . The NH 2 terminus of STIM1 is located in the ER/SR lumen and includes a canonical EF-hand domain (cEF), a non-Ca 2ϩ binding hidden EF-hand domain (hEF), and a sterile alpha motif domain (SAM). Although Ca 2ϩ binds only to the cEF domain, the stability of the whole EF-hand-SAM domain is important for its Ca 2ϩ sensing role (114, 115) . In the resting condition, the NH 2 -terminal region forms a monomeric tight and stable EF-hand-SAM complex, which has a relatively low Ca 2ϩ binding affinity (57, 110) compatible with the role of STIM1 as a Ca 2ϩ sensor. When ER/SR Ca 2ϩ stores are decreased, STIM1 releases Ca 2ϩ from the cEF domain, resulting in the exposure of hydrophobic residues in the EF-hand-SAM complex, thereby initiating STIM1 oligomerization (9, 140) .
In the cytosol, proximal to the ER/SR membrane, is an ezrin/radixin/moesin domain, which includes three coiled-coils (CC) and an acidic inhibitory domain (ID). CC1 consists of three ␣-helices; CC2 and CC3a comprise the STIM1-Orai activating region (SOAR), which is the minimal domain required and sufficient for the activation of SOCE by Orai1 (144) . Under resting conditions, interactions between the CC domains maintain STIM1 in a dimeric state with the SOAR domain bound to the C␣3 inhibitory helix within the CC1 region (67) . Ca 2ϩ release from the EF-hand-SAM domain leads to elongation of the CC1 domain, exposing the SOAR domain and further enhancing STIM1 oligomerization. The activated STIM1 oligomers form a robust multivalent interaction, which confines STIM1 to the ER/SR-PM junctions as well as providing the subsequent driving force for the tight assembly of STIM1-store-operated Ca 2ϩ channel (SOC) complexes in these specialized ER/SR subregions (7). Interestingly, Zeng et al. (147) demonstrated ER/SR STIM1 oligomerization in the absence of store-depletion, with STIM1 clustering in cytosolic regions rather than plasma membrane junctions, and no Ca 2ϩ entry. Although the physiological relevance of this observation remains to be determined, it does show that STIM1 oligomerization and translocation can be dissociated from each other.
The COOH-terminal region contains a Proline/Serine-rich domain (PS), a microtubule interacting domain (TRIP), and a lysine-rich polybasic domain (K). The K domain is predicted to contain a flexible central amphipathic ␣-helix that is flanked by globular positively charged regions in a dumbbell-like structure (148) . The region between the ID and K domains appears to be the major regulatory region and contains most of the currently identified phosphorylation sites (62, 92, 109, 143) . Although it is now well recognized that STIM1 is a phosphoprotein (31, 62) , the molecular pathways responsible for controlling STIM1 phosphorylation are not well defined and the physiological function of many of the phosphorylation sites remain to be identified. During mitosis STIM1 phosphorylation of Serine 486 and 668 by Cyclin-dependent kinase 1 attenuated both STIM1 oligomerization and SOCE (109 depletion, Ca 2ϩ dissociates from STIM1, resulting in a conformational change initiated by the SAM domain, followed by extension of the CC1 cytosolic domain, resulting in STIM1 oligomerization. The STIM1 oligomers then translocate to the ER/SR-PM junction through the electrostatic interaction between the K domain and the negative charged phospholipids in the plasma membrane, where it interacts with and activates Orai1 leading to SOC entry (SOCE). It should be noted that under resting conditions Orai1 consists of either a homodimer or homotetramer, whereas upon activation it forms a hexamer.
is required for thapsigargin-induced activation of SOCE by enhancing STIM1-Orai1 coupling (92) . In neonatal cardiomyocytes we have shown that activation of SOCE by thapsigargin also increases STIM1 phosphorylation (153) . Currently, little is known about the mechanisms responsible for reversing SOCE; however, this presumably involves dissociation of STIM1-Orai1 complex and subsequent disruption of STIM1 oligomers. This could be regulated either through changes in the phosphorylation of STIM1 and/or its interacting proteins, as well as via conformational changes in STIM1 resulting from refilling of ER/SR Ca 2ϩ stores. Interestingly, the STIM1/Orai1 complex appears to be regulated by the kinases SGK-1 and AMPK, which may reduce unnecessary SOCE when energy reserves are low (48) . In addition, the ER membrane protein SARAF, also known as transmembrane protein 66, has been shown to associate with STIM1 in the ER, acting as a regulator of SOCE inactivation to prevent excess Ca 2ϩ refilling of the stores (81) . Also the ER protein Surfeit locus protein 4 binds to STIM1 and modulates STIM1-dependent SOCE (23) . In pulmonary arterial smooth muscle cells inhibition of Akt decreased SOCE, indicating a potential role for Akt in regulating SOCE (75) . In addition, Li et al. (52) reported that Akt activation is reduced in STIM1 knockout mice, providing further support for a relationship between STIM1 and Akt; however, it remains to be determined whether Akt directly phosphorylates or regulates STIM1. It should be noted that although our understanding of the molecular regulation of STIM1 function is growing rapidly, most if not all this information is derived from nonexcitable cells; therefore, additional studies are needed to determine whether the same or different mechanisms are involved in STIM1 regulation in excitable cells such as cardiomyocytes.
When compared with STIM1, STIM2 has a distinctly different NH 2 -terminal region (Fig. 2) , but contains a similar EF-hand-SAM domain and a variable COOH terminus, which lacks the Pro/Ser-rich domain, but includes a Pro/His-rich domain and a longer flexible tail (31, 56, 136) . Despite the similarities with STIM1, the role of STIM2 in regulating SOCE remains poorly understood. For example, STIM2 overexpression alone has been reported to inhibit SOCE, whereas co-expression of STIM2 with Orai1 induced both store-dependent and independent Ca 2ϩ entry (56, 88, 112) . To date there have been no studies on the potential role of STIM2 in the heart. It should also be noted that STIM1L, a novel high molecular weight STIM1 splice variant (130kD vs 80kD; Fig.  2 ), has recently been described and is highly expressed in skeletal muscle (10) and is also present in cardiomyocytes (59) . It consists of an actin-binding site and forms a permanent stable cluster with actin in the t-system, potentially facilitating an immediate and repetitive activation of SOCE (10); however, its functional role remains to be investigated.
STIM1 and the molecular regulation of SOC. Although STIM1 acts as the sensor of ER/SR Ca 2ϩ levels, and STIM1 oligomerization is critical for activation of SOCE, it is ultimately the interaction between STIM1 and plasma membrane proteins that is required for facilitating Ca 2ϩ entry into the cell. Two types of SOC pore-forming subunits have been described and are illustrated in Fig. 3 , including Ca 2ϩ release-activated Ca 2ϩ modulator (CRACM1), more commonly referred to as Orai1 (22, 89, 93, 128, 129, 142, 149) , and TRPCs (110, 135 Fig. 2 . Comparison of structural features of STIM1, STIM1L, and STIM2 proteins. All proteins include a signal peptide, a cEF-hand-SAM, a transmembrane domain (TM), coiled-coil domains (CC), and a lysine-rich domain (K). STIM1L is identical to STIM1 except for the presence of an extra actin-binding domain (ABD) following its coiled coil domains. STIM2 has a distinct upstream and a longer flexible tail containing a proline/histidine-rich domain (PH), but lacks the proline/serine rich domain (PS) seen in STIM1 and STIM1L. Orai1 is the founding member of the Orai protein family, which also includes two highly conserved homologs, Orai2 and Orai3, although the physiological roles of Orai2 and Orai3 are less well defined compared with Orai1.
Orai1/TRPC
Orai1 consists of four transmembrane domains (15, 34, 106) and under resting conditions is reported to exist either as a homodimer (14) or homotetramer (60); upon activation it forms a hexamer (34) and mediates I CRAC , a highly Ca 2ϩ -selective (P Ca /P Na Ͼ 1,000) and nonvoltage-gated current with a barely discernible single channel conductance (Ͻ18 -24 fS in 100 mM Ca 2ϩ ) and a pronounced inward-rectifying currentvoltage (I-V) relationship (49, 53, 74) . The activation kinetics of Orai1 are relatively slow and determined by the rate of Ca 2ϩ depletion as well as the translocation rate of both STIM1 and Orai1 to ER/SR-PM junctions; however, the duration of Orai1 activation can be sustained with prolonged store depletion (110) . Although it is widely recognized that Orai1 is highly Ca 2ϩ selective, recent studies have demonstrated that this Ca 2ϩ -selectivity is actually determined by the binding of STIM1 and that intrinsically Orai1 has poor Ca 2ϩ selectivity (65) . TRPCs are relatively nonselective cation channels (P Ca / P Na Ͻ 10) (152), conducting inward currents carried by both monovalent and divalent cations including Na ϩ , Ca 2ϩ , Ba 2ϩ , and Sr 2ϩ . This subfamily includes seven members (TRPC1-TRPC7) that exhibit various properties, regulation mechanisms, and physiological functions. Interestingly, in 1996, almost a decade before STIM1 was discovered, TRPC1 had been identified as a potential SOC candidate (154) , and this was subsequently confirmed in many cell types including both nonexcitable and excitable cells (84, 138, 139) . Although the role of other TRPCs (TRPC2-7) in SOCE remains poorly understood, over the last decade TRPC3 (79), TRPC4 (71), and TRPC6 (79) have all been implicated in SOCE-mediated hypertrophic signaling in cardiomyocytes.
It is generally accepted that TRPCs are activated downstream of agonist-stimulated PIP 2 hydrolysis; however, TRPCs do not appear to contribute to I CRAC (8) . Consequently, TRPCmediated store-operated currents are broadly classified as I SOC to distinguish them from the highly Ca 2ϩ -sensitive Orai1-mediated I CRAC . It should also be noted that the STIM1 SOAR domain is sufficient to activate Orai1; however, this is not the case for TRPC1, where the K domain is required for TRPC1 gating (35) . Furthermore, in contrast with STIM1-Orai1, the STIM1-TRPC1 SOC is less selective for Ca 2ϩ and, consequently, more permissive of other divalent cations (2, 8, 74, 84, 106) . Our current understanding, therefore, is that STIM1 is required for activation of both Orai1 and TRPC1-mediated SOC, but that STIM1-Orai1 coupling is highly Ca 2ϩ selective and is responsible for I CRAC , whereas STIM1-TRPC1 coupling is less selective and contributes to I SOC (Fig. 3) . It has also been postulated that STIM1 could interact with a plasma membrane TRPC1-Orai1 complex (106); however, this putative SOC has yet not been characterized.
Store-independent mechanisms of STIM1. Although much of the focus on STIM1 has been on its role in SOCE, it should be noted that it has also been shown to contribute to storeindependent Ca 2ϩ entry, more specifically the activation of the arachidonic acid-regulated calcium (ARC) channels (108, 119) . ARC channels have very similar biophysical characteristics to SOC channels, have been shown to contribute to agonist-induced Ca 2ϩ entry, and are also dependent on STIM1 for activation; a key difference, however, is that ARC channels are dependent on a plasma membrane pool of STIM1, which is estimated to be 15-25% of total cellular STIM1 (119). Another difference is that although the SOC consists of six homomeric Orai1 subunits, activated ARC channels are heteromeric, consisting of both Orai1 and Orai3 subunits. Moreover it has been reported that activation of ARC channels is solely dependent on cytosolic COOH-terminal domain of STIM1 and that the NH 2 -terminal region of STIM1 plays no role in this activation (119) . To date there have been no reports of ARC channel activity in cardiomyocytes; however, further studies are clearly warranted to explore this in more detail. In addition to its role in regulating SOCE, STIM1 may also contribute to the maintainance of ER/SR structure. For example, Grigoriev et al. (26) 
2ϩ signaling can result in ER stress and subsequent activation of the unfolded protein response, it is possible that STIM1 may also contribute to the regulation of the ER stress response. In support of this, Stanniocalcin 2 (Stc), an ER stress protein, has been shown to colocalize with STIM1 and decreased Stc expression led to increased SOCE, whereas increased Stc levels attenuated SOCE (146) . In addition, the ER stress protein ERp57 has been shown to interact with STIM1 and modulate SOCE (94). Henke et al. (30) also found that in STIM1-deficient cells there was increased phosphorylation of EReIF2␣ and PERK, further supporting a role for STIM1 in mediating ER stress response.
Evidence of SOCE in cardiomyocytes. In cardiomyocytes, voltage-gated Ca 2ϩ entry, which is essential for excitationcontraction (EC) coupling, is recognized as the predominant pathway for extracellular Ca 2ϩ entry. Moreover, in the most widely accepted models of Ca 2ϩ homeostasis, Ca 2ϩ involved in the activation of signal transduction pathways in cardiomyocytes is released either from the SR or nuclear envelope predominantly in an IP 3 -mediated process, and to date these models have not included SOCE pathways (5, 13, 42) . However, in 2002 this laboratory (38) and Uehara and colleagues (122) demonstrated that Ca 2ϩ store depletion in neonatal and embryonic cardiomyocytes, respectively, resulted in a robust and persistent influx of extracellular Ca 2ϩ that was blocked by SOC inhibitors but not inhibitors of either L-type Ca 2ϩ channels (LTCC) or Na ϩ /Ca 2ϩ exchangers (NCX). We first reported the presence of SOCE in adult cardiomyocytes in 2004 using the combination of thapsigargin and the IP 3 -generating agonist ANG II (39) . Using a differential dye-loading protocol to measure both ER/SR and cytosolic Ca 2ϩ levels, we observed a significant increase in cytosolic Ca 2ϩ concomitant with an immediate drop in store Ca 2ϩ levels, consistent with the activation of SOCE (39) . Whole cell patch-clamp experiments provided further evidence that SOCE was activated upon the depletion of ER/SR Ca 2ϩ stores in isolated adult cardiomyocytes (39) . Interestingly, in cardiomyocytes SOCE appears to be developmentally dependent, with a greater amplitude in embryonic cardiomyocytes than adult cardiomyocytes, which most likely reflects the substantial developmental changes in Ca 2ϩ handling that occur between embryonic and adult hearts. Taken together, these studies demonstrate the existence of SOCE in embryonic, neonatal, and adult cardiomyocytes independent of other ion channels.
Support for the presence of cardiac SOCE has been strengthened by the identification of the molecular mediators of SOCE in cardiac tissue. Ohba et al. (77) identified STIM1 protein expression in both the neonatal and adult rat heart and, consistent with the earlier findings of Voelkers et al. (130), we have recently shown the expression of both STIM1 and Orai1 protein in neonatal rat ventricular myocytes as well as in the intact adult rat heart (153) . The existence of SOCE and expression of both STIM1 and Orai1 have also recently been shown to occur in HL-1 cardiomyocytes, an immortalized mouse atrial cell line (120). We and others have shown that in neonatal cardiomyocytes Ca 2ϩ store depletion induced STIM1 puncta formation, consistent with that seen in nonexcitable cells (37, 153) . We also demonstrated that in neonatal cardiomyocytes SOCE was highly selective for Ca 2ϩ , confirming that SOCE was primarily mediated by STIM1-Orai1 coupling rather than STIM1-TRPC1 (153) .
Physiological role of SOCE in the heart. The evidence that both SOCE and the molecular machinery characteristic of SOCE in nonexcitable cells are present in cardiomyocytes raises the question as to the underlying physiological role of SOCE in the heart. This is particularly important given that the widely accepted models of cardiomyocyte Ca 2ϩ homeostasis do not include SOCE pathways (5, 13, 42) . In 2002 we reported that the physiological IP 3 -generating agonists phenylephrine (PE) and ANG II induced an increase in cytosolic Ca 2ϩ that was dependent on extracellular Ca 2ϩ (38) . In the same study, we also demonstrated that PE and ANG II-induced nuclear translocation of NFAT was dependent on extracellular Ca 2ϩ and required for the subsequent induction of cardiomyocyte hypertrophy. Importantly, the hypertrophic responses to PE and ANG II were not affected by LTCC or NCX inhibitors, but were blunted by inhibitors of SOCE. Of note, hypertrophy induced by overexpression of MEK1 was unaffected by inhibitors of SOCE, indicating that the hypertrophic effects of SOCE were specific for Ca 2ϩ -mediated cardiac hypertrophy. In addition to stimulating cardiomyocyte hypertrophy, PE, an ␣-adrenergic agonist, is a potent positive inotropic agent in the heart. Interestingly, we reported that treatment of the isolated perfused heart with the SOCE inhibitor SKF96365 significantly blunted the response to PE compared with untreated control hearts (82) . In contrast, inhibition of NCX, which is also reportedly activated by PE (116), had no effect on PEinduced inotropic response (82) . Notably, SKF96365 had no effect on the positive inotropic response to the ␤-adrenergic agonist isoproterenol, demonstrating that SOCE appears to be specific in mediating the effects of ␣-adrenergic and not ␤-adrenergic agonists (82) . This specificity is likely due to the fact that unlike ␣-adrenergic agonists, ␤-adrenergic agonists do not generate IP 3 and do not lead to Ca 2ϩ store depletion. These initial studies occurred before the identification of STIM1 and Orai1 as key mediators of SOCE, and clearly a great deal remains to be understood about the normal physiological role of STIM1-mediated SOCE in the heart. A recent study of endothelial cell function demonstrated that a decrease in STIM1 protein levels observed in response to hyperglycemia was associated with a decrease in total ER Ca 2ϩ content, and restoration of STIM1 protein to normal levels restored ER Ca 2ϩ levels (19) . Although it remains to be determined whether this is also the case in cardiomyocytes, this study raises the possibility that, in addition to contributing to ␣-adrenergic and hypertrophic signaling, STIM1 could also contribute to the regulation of basal SR/ER Ca 2ϩ levels in cardiomyocytes. On the other hand, it should be noted that Luo et al. (59) found no effect of either increasing or decreasing STIM1 levels on SR Ca 2ϩ content in neonatal cardiomyocytes. Of note, inactivation of the Orai1 ortholog in zebrafish resulted in the development of heart failure and progressive loss of skeletal muscle myofiber integrity (131) . Furthermore, in Orai1-deficient cardiomyocytes, the calcineurin-associated protein calsarcin was lost from the z-discs and mechanosignal transduction was impaired (131) . Although these data support the notion that defects in SOCE are associated with significant cardiovascular complications, it should be noted that humans and mice with reduced STIM1 expression primarily exhibit extensive immunodeficiency and skeletal muscle pathology, with no signs of overt cardiovascular pathology (21) . However, because humans lacking Orai1 or STIM1 succumb to immunodeficiency in their first years of life, the impact of a sustained lack of STIM1 on the heart may not be apparent.
Recent studies have also indicated a link between activation of Orai1 and Orai3 SOC and the initiation of arrhythmias in both atrial and ventricular myocytes (132, 137) , suggesting that Orai-mediated SOCE may be an important regulator of myocardial electromechanical stability. In addition, Nguyen et al. (73) have shown that in HL 1 cells, a reduction in STIM1 expression was sufficient to disrupt contraction, induce Ca 2ϩ oscillations and associated arrhythmias as well as increased TTCC activity and expression. Taken together, these studies provide strong support for a key role for STIM1/Orai1-mediated SOCE in regulating cardiomyocyte Ca 2ϩ homeostasis. Several groups have also suggested that SOCE may contribute to the regulation of basal Ca 2ϩ homeostasis in the heart. Li et al. (51) reported that Junctophilin knockout myotubes had reduced SOCE, decreased STIM1, Orai1, and TRPC1/3 protein expression as well as lower basal Ca 2ϩ levels compared with wild-type cells. Furthermore, in HL-1 cells knockdown of Orai1 decreased SOCE as well as both cytosolic and SR Ca 2ϩ levels (120) . In addition, binding of STIM1 to LTCC has been shown to inhibit these channels (87, 133) . Further support for potential cross-talk between SOCE and EC coupling-mediated Ca 2ϩ pathways is provided by observations in skeletal muscle that dihydropyridine receptors and ryanodine receptors colocalize within preformed SR-PM junctions, where STIM1-Orai1 channels occur (17) , as well as reports of a storeoperated calcium entry signaling complex, in which STIM1, Orai1, TRPC channels, and sarco(endo)plasmic reticulum Ca 2ϩ -ATPase come together to mediate and modulate SOCE (123) . Nevertheless, the relationship between SOCE and EC coupling remains poorly understood.
SOCE, STIM1, and cardiac hypertrophy. Cardiac hypertrophy occurs as an adaptive growth response to cardiac stressors such as myocardial infarction and hypertension-induced pressure-overload. Sustained increases in intracellular Ca 2ϩ are known to activate signaling pathways such as the calcineurin/ NFAT pathway, which are responsible for the development of hypertrophy. As described above in one of the earliest studies demonstrating that SOCE was present in cardiomyocytes, we reported that SOCE activated hypertrophic signaling pathways were mediated via NFAT nuclear translocation (38) . Histori-cally, TRPC channels were among the first potential mediators of SOCE, and they have also been implicated in SOCEinduced cardiac hypertrophy. Nakayama et al. (71) showed that calcineurin/NFAT-mediated signaling and hypertrophy were dependent on TRPC4. In addition, TRPC3 and TRPC6 have also been shown to contribute to the development of ANG II-induced hypertrophy (79) , and SOCE and NFAT translocation have been shown to be increased in HEK293 cells overexpressing TRPC1 (78) . Interestingly, as recently as 2011, although describing the significance of SOCE in cardiomyocytes as a mystery, Eder and Molkentin nevertheless concluded that "TRPC channels are bona fide regulators of cardiac hypertrophy associated with pathological events and neuroendocrine signaling" (18) .
Because of the identification of STIM1 and Orai1 as potential mediators of SOCE, focus has shifted toward the role of these proteins in SOCE-induced cardiac hypertrophy. Ohba and colleagues were among the first to demonstrate a potential role for STIM1 in mediating cardiac hypertrophy (77) . Similar to our earlier studies with PE and ANG II (38), they demonstrated that in neonatal cardiomyocytes endothelin-1 (ET-1) induced activation of SOCE, NFAT nuclear translocation, and cardiomyocyte hypertrophy; importantly, however, all were attenuated following knockdown of STIM1. Similar to their earlier study (78) , they also found that TRPC1 expression was upregulated in response to ET-1; interestingly, this increase was also attenuated following knockdown of STIM1. Subsequently, Voelkers and colleagues showed that SOCE and hypertrophic signaling induced by PE treatment were reduced following knockdown of both STIM1 and Orai1 (130) .
Further support for the role of STIM1-mediated SOCE in the development of hypertrophy was provided by Luo et al. (59) , who found that STIM1 levels were low in the adult heart but increased substantially in response to transaortic constrictioninduced hypertrophy, and this was associated with an increase of SOCE (59) . Transfection of cardiomyocytes with constitutively active-STIM1 was sufficient to increase hypertrophy and protein synthesis, and this was augmented by treatment with PE. They also found that the high molecular weight STIM1 splice variant STIM1L also increased in response to hypertrophic stimuli; however, the significance of this finding remains to be determined. In addition, Hulot and colleagues (37) reported that STIM1 was both sufficient and necessary for cardiomyocyte hypertrophy both in vitro and more importantly in the adult heart in vivo; moreover, in vivo STIM1 gene silencing protected the heart from pressure overload-induced hypertrophy. These authors also showed that SOCE was significantly increased following cardiac hypertrophy, which was attenuated by STIM1 knockdown.
Overall these studies strongly support a role for STIM1, specifically STIM1-mediated SOCE, as playing a key role in regulating cardiac hypertrophy, induced either by IP 3 -generating agonists or following pressure overload. These data further suggest that the increase in STIM1 protein that occurs in response to hypertrophic stimuli may be part of the activation of the fetal gene program, which is characteristic of stressed cardiomyocytes. Although STIM1 appears to be required and sufficient for cardiomyocyte hypertrophy, additional studies are clearly necessary to determine the relative importance and roles of Orai1 and TRPCs in mediating this response.
Potential role for STIM1-mediated SOCE in ischemia/reperfusion injury.
Calcium overload is a key mediator of acute ischemia/reperfusion (I/R) injury and historically the primary mechanisms leading to lethal Ca 2ϩ overload during ischemia have been the coupling of the Na ϩ -H ϩ exchanger with reversal of the NCX and, to a lesser extent, voltage-gated LTCCs (69). However, therapeutic approaches targeting these pathways, specifically at reperfusion, have typically proven unsuccessful (141) . Our earlier studies demonstrated that glucosamine inhibits SOCE in both nonexcitable cells as well as cardiomyocytes (38, 70, 83) , and we have demonstrated that glucosamine protects the heart against Ca 2ϩ overload induced by the Ca 2ϩ paradox as well as against acute I/R injury (55) . This raises the intriguing notion that the SOCE pathway could be a key mediator of I/R-induced Ca 2ϩ overload. In support of this concept, following ischemia in the isolated perfused heart, SR Ca 2ϩ levels were observed to decrease rapidly at reperfusion (124) , which is of course a key step in the activation of SOCE. Furthermore, Mancarella et al. (61) reported that hypoxia stimulated STIM1 accumulation at ER-plasma membrane junctions, whereas the accompanying acidosis uncoupled the STIM1-Orai1 complex, thereby preventing Ca 2ϩ overload. Although not in cardiomyocytes, this study suggests that ischemia, which is also characterized by hypoxia and acidosis, could be a trigger for the molecular machinery required for SOCE to be positioned for rapid activation upon reperfusion when the acidosis is quickly resolved. Mungai et al. (68) also reported that hypoxia triggered STIM1 translocation to plasma membrane junctions in an apparently reactive oxygen speciesdependent manner, providing further support for a role of hypoxia in the regulation of STIM1-mediated SOCE.
Pharmacological inhibition of SOCE with gadolinium (Gd 3ϩ ) and 2-aminoethoxydiphenyl borate (2-APB) abolished Ca 2ϩ overload in cardiac microvascular endothelial cells subjected to I/R (91), providing additional evidence that SOCE pathways contribute to Ca 2ϩ overload associated with I/R. In adult mouse cardiomyocytes, 2-APB, Gd 3ϩ , and La 3ϩ , all inhibitors of SOCE, were shown to attenuate Ca 2ϩ overload induced by the Ca 2ϩ paradox (44), consistent with the concept that SOCE is a key mediator of Ca 2ϩ overload. We also found that isolated cardiomyocytes from transgenic mice overexpressing TRPC3 subjected to I/R exhibited increased apoptosis and increased calpain activation compared with wild-type cardiomyocytes, which was attenuated by SKF96365, also consistent with the notion that the increased I/R injury is mediated by SOCE (107) . One consequence of I/R injury is the increased incidence of ventricular arrhythmias; preliminary studies showed that in adult mouse cardiomyocytes subjected to ischemic conditions there was increased spontaneous Ca 2ϩ release and that this was blocked by Gd 3ϩ , an inhibitor of SOCE, suggesting that spontaneous Ca 2ϩ release and resultant arrhythmias may be mediated at least in part by SOCE (134) . It should be noted, however, that Gd 3ϩ is a nonspecific cation channel inhibitor; therefore interpretation of results based on Gd 3ϩ need to be made with caution. Nevertheless, these data support earlier findings of Huang et al. (36) who showed that in neonatal rabbit cardiomyocytes increased SR Ca 2ϩ content and resultant arrhythmic activity could be attenuated by SKF96365. In addition, TRPC channel expression and SOCE have both been shown to occur in pacemaker cells such as those of the sinoatrial node (41, 105) . Also as noted earlier, increased Orai-mediated SOCE has been implicated in initiation of atrial and ventricular arrhythmias (132, 137) and we reported that in the isolated perfused heart glucosamine, which inhibits SOCE, decreased the incidence of arrhythmias following I/R (25) . Therefore, with hypoxia activating STIM1 accumulation in plasma membrane junctions (61) , combined with a rapid decrease in SR Ca 2ϩ levels at reperfusion (124), the stage is set for uncontrolled SOCE contributing to Ca 2ϩ overload, a key mediator of early I/R injury, and a potential trigger for arrhythmogenesis. This is supported by observations in a range of different model systems demonstrating that pharmacological inhibition of SOCE blunts Ca 2ϩ overload and attenuates I/Rinduced arrhythmias. Thus considerable circumstantial evidence exists to support the concept that STIM1-mediated SOCE at reperfusion may represent a major pathway for I/R-induced Ca 2ϩ overload; however, further studies are clearly warranted to better understand the role of SOCE as a mediator of cardiac I/R injury.
Interactions between STIM1-mediated SOCE and metabolic signaling in the heart. In 1995 Marchase and colleagues (101) reported that in smooth muscle cells SOCE was inhibited by hyperglycemia; in subsequent studies they demonstrated that this also occurred in macrophages and cardiomyocytes (11, 83, 125) . More recently, platelets from type 2 diabetic patients were found to have decreased SOCE and attenuated association between STIM1, Orai1, and TRPC1/6 (40) . In addition, we have reported that hypertrophic signaling in cardiomyocytes, which as discussed earlier is SOCE dependent, was attenuated in diabetic mice (63) . Estrada et al. (19) demonstrated that endothelial cells from diabetic mice were found to have reduced ER Ca 2ϩ and significantly decreased STIM1 protein levels compared with nondiabetic mice; subsequent overexpression of STIM1 restored ER Ca 2ϩ levels and improved endothelium-dependent relaxation of diabetic coronary arteries. They also found that endothelial cells from normal animals exposed to hyperglycemia exhibited changes in ER Ca 2ϩ and STIM1 levels similar to those seen in response to diabetes (19) .
Collectively, these observations suggest that SOCE is sensitive to changes in glucose homeostasis and that hyperglycemia-induced attenuation of SOCE could be a contributing factor to the adverse effects of diabetes on various cell types including endothelial cells, vascular smooth muscle cells, and cardiomyocytes; however, the mechanism(s) by which glucose might regulate SOCE are not clear. Although glucose is primarily considered as an energy source, there is growing evidence that the energy-independent effects of glucose can be attributed to its metabolism via the hexosamine biosynthesis pathway and subsequent modification of nuclear and cytosolic proteins by O-linked N-acetylglucosamine (O-GlcNAc). This post-translational protein modification, first identified in the mid-1980s, has garnered increasing interest in recent years as a mechanism by which changes in metabolism, particularly glucose, are transduced into alterations in protein function. Protein O-GlcNAcylation has been shown to be involved in numerous cellular processes including signal transduction, protein trafficking, protein-protein interactions, protein degradation, and regulation of gene expression and cell survival responses (12, 72, 145) . Increased O-GlcNAc levels have also been implicated in contributing to the adverse effects of hyperglycemia in a wide range of tissues and cells, and sustained O-GlcNAcylation is now widely appreciated as a pathogenic mediator of diabetic complications (16, 28, 46, 64) .
Marchase and colleagues (70, 83) found that glucosamine, an amine sugar that selectively fuels the hexosamine biosynthesis pathway, mimicked the effects of hyperglycemia and further that inhibition of glucose entry into the hexosamine biosynthesis pathway blocked the effects of hyperglycemia on SOCE. We have also reported that the ANG II-induced increase in cytosolic Ca 2ϩ was attenuated in cardiomyocytes by increasing O-GlcNAc levels, further supporting the concept that SOCE might be directly regulated by O-GlcNAcylation (70) . O-GlcNAc modification sites are frequently the same serine and threonine sites that are subject to phosphorylation; therefore, because STIM1 is regulated by phosphorylation, we postulated that the effects of hyperglycemia and O-GlcNAc on SOCE could be due to O-GlcNAcylation of STIM1. In a recent study we demonstrated that increasing O-GlcNAc levels attenuated STIM1 puncta formation and subsequent SOCE (153) . We also showed that STIM1 was a target for O-GlcNAcylation and that increasing STIM1 O-GlcNAc levels significantly modulated STIM1 phosphorylation (153) . It should also be noted that in addition to diabetes, chronic or sustained increases in O-GlcNAc levels in the heart have been shown in cardiac hypertrophy (20, 58) and in the aged heart (24) and acute increases in O-GlcNAc are clearly cardioprotective (47, 55) . Therefore, although additional studies are clearly needed to better understand the interrelationship between O-GlcNAcylation, STIM1 function, and regulation of SOCE, this represents a potentially novel mechanism linking metabolic and calcium signaling pathways.
In addition to their central role in energy production, mitochondria are also widely recognized as contributing to cellular homeostasis through regulation of reactive oxygen species and cytosolic Ca 2ϩ levels. Recently, Henke et al. (30) reported that STIM1 and Orai1 knockdown increased sensitivity of cells to oxidative stress and that the converse was also true. Moreover, in STIM1 null cells they found that normal mitochondrial structure was disrupted and metabolic rate increased. It has also been shown that STIM1 is s-glutathionylated in response to oxidative stress, resulting in increased SOCE and altered mitochondrial Ca 2ϩ homeostasis (29) ; however, contrary to the work of Henke et al. (30) they found that a reduction in STIM1/Orai1 is protective in terms of oxidative stress. These studies provide evidence that STIM1 contributes to the regulation of both mitochondrial homeostasis and oxidative stress. Although these studies did not use cardiomyocytes, one can imagine that disruption of normal STIM1 function could be even more important in cardiomyocytes, which are dependent on tight control of mitochondrial function for efficient energy production.
Conclusions
Given the recent evidence that the molecular machinery required for SOCE is present in cardiomyocytes, combined with more than a decade of studies demonstrating that SOCE occurs in embryonic, neonatal, and adult cardiomyocytes, it is increasingly clear that this Ca 2ϩ entry pathway co-exists with the EC coupling Ca 2ϩ -handling pathways in the heart (Fig. 4) . Consistent with what has been reported in nonexcitable cells, STIM1 appears to be a critical mediator of SOCE, whereas the relative importance of Orai and TRPCs plasma membrane channels is much less understood and may well be dependent on the specific stimulus used to activate this pathway. The evidence for SOCE playing a pathophysiological role in the heart is strongest in the context of cardiac hypertrophy, where STIM1-mediated SOCE has been shown to be both required and sufficient for cardiomyocyte hypertrophy. There is, however, also strong circumstantial evidence that SOCE may contribute to I/R-induced Ca 2ϩ overload. The fact that STIM1 is O-GlcNAcylated and that this impairs its function and attenuates SOCE raises the intriguing notion that STIM1 could represent a key mechanism for integrating metabolic and Ca 2ϩ signaling. However, there is no doubt that much remains to be understood about STIM1 and SOCE in the heart, including how Ca 2ϩ influx through this pathway is segregated from large beat-to-beat changes in cytosolic Ca 2ϩ required for EC coupling and the extent to which SOCE is involved in regulating basal cardiomyocyte Ca 2ϩ homeostasis. A key limitation in the study of SOCE in general and more specifically STIM1-mediated SOCE is the lack of specificity of currently available pharmacological inhibitors (85) . There are some recent studies examining derivatives of 2-ABP in SOCE inhibition, but there was no evaluation as to selectivity relative to other calcium entry pathways (32) , which would be essential for use in cardiomyocytes. Given our growing appreciation of the importance of STIM1-mediated SOCE in cardiovascular pathophysiology, there is a clear need for the development of new pharmacological inhibitors of this pathway, with substantially increased specificity. The availability of such inhibitors would not only provide valuable new mechanistic insights into STIM1 regulation and function but could also provide the foundation for development of novel therapeutics for the treatment of cardiovascular disease.
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